on ABIONYX (EPA:ABNX)
ABIONYX Pharma is expanding rapidly following its General Meeting
ABIONYX Pharma, a biopharmaceutical company, announced a significant expansion following its Combined General Meeting. All proposed resolutions were adopted, paving the way for new ambitions. Among the flagship projects is the launch of a pivotal clinical phase for CER-001 in sepsis, scheduled before the end of 2026, with results expected in the first half of 2028.
The company has secured €33 million to guarantee the development of its strategic programs, including the approval of CER-001 for the LCAT deficit. This phase is accompanied by a focus on optimizing their proprietary scientific platform based on apoA-I, and developing new industrial partnerships.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIONYX news